NeuroSense Therapeutics (NRSN) Income from Continuing Operations (2021 - 2024)
NeuroSense Therapeutics (NRSN) posted Income from Continuing Operations of 18619000.0 for Q4 2024, up 226.92% sequentially from 14670000.0 in Q3 2024, and up 684.22% YoY from 2374214.9 in Q1 2024.
NeuroSense Therapeutics (NRSN) Income from Continuing Operations (2021 - 2024) Analysis & Trends
NeuroSense Therapeutics has reported Income from Continuing Operations for 4 years, with the latest figure at 18619000.0 in Q4 2024.
- Quarterly Income from Continuing Operations rose 684.22% year-over-year to 18619000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 10210000.0 (up 201.02% YoY) and the FY2025 annual result came in at 11125000.0, up 8.96% from the prior year.
- Income from Continuing Operations advanced to 18619000.0 in Q4 2024 per NRSN's latest filing, from 14670000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 19682000.0 in Q4 2022 and troughed at 15386000.0 in Q3 2022.
- A 4-year average of 1637928.57 and a median of 1532500.0 in 2022 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 684.22% in 2024, down 4091.43% in 2024.
- Over 4 years, Income from Continuing Operations stood at 7160000.0 in 2021, then soared by 174.89% to 19682000.0 in 2022, then tumbled by 116.19% to 3187000.0 in 2023, then surged by 684.22% to 18619000.0 in 2024.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 18619000.0, 14670000.0, and 11665000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | NeuroSense Therapeutics | 9.68 Mn | 9.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 18.62 Mn |
| Sep 30, 2024 | -14.67 Mn |
| Jun 30, 2024 | 11.67 Mn |
| Mar 31, 2024 | -5.40 Mn |
| Dec 31, 2023 | -3.19 Mn |
| Sep 30, 2023 | -350,000.00 |
| Jun 30, 2023 | -3.65 Mn |
| Mar 31, 2023 | -2.92 Mn |
| Dec 31, 2022 | 19.68 Mn |
| Sep 30, 2022 | -15.39 Mn |
| Jun 30, 2022 | 8.91 Mn |
| Mar 31, 2022 | -2.72 Mn |
| Dec 31, 2021 | 7.16 Mn |
| Jun 30, 2021 | 5.18 Mn |